Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PET ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pheochromocytoma and paraganglioma.N Engl J Med. 2019; 381: 552-565
- Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979.Mayo Clin Proc. 1983; 58: 802-804
- Incidence of pheochromocytoma and sympathetic paraganglioma in The Netherlands: a nationwide study and systematic review.Eur J Intern Med. 2018; 51: 68-73
- The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.Pancreas. 2010; 39: 775-783
- Adrenal pheochromocytoma remains a frequently overlooked diagnosis.Am J Surg. 2000; 179: 212-215
- Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and auckland.Aust N Z J Med. 2000; 30: 648-652
- Phaeochromocytoma Lancet. 2005; 366: 665-675
- Pheochromocytoma characteristics and behavior differ depending on method of discovery.J Clin Endocrinol Metab. 2019; 104: 1386-1393
- Update on pheochromocytoma and paraganglioma from the sso endocrine/head and neck disease-site work group. part 1 of 2: advances in pathogenesis and diagnosis of pheochromocytoma and paraganglioma.Ann Surg Oncol. 2020; 27: 1329-1337
- Supportive management of patients with pheochromocytoma/paraganglioma undergoing noninvasive treatment.Curr Opin Endocrinol Diabetes Obes. 2022; 29: 294-301
- Personalized management of pheochromocytoma and paraganglioma.Endocr Rev. 2022; 43: 199-239
- Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review.Q J Nucl Med Mol Imaging. 2013; 57: 122-133
- Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol.Clin Nucl Med. 2014; 39: 243-250
- Metabolic subtyping of pheochromocytoma and paraganglioma by (18)f-fdg pharmacokinetics using dynamic PET/CT scanning.J Nucl Med. 2019; 60: 745-751
- Usefulness of FDG-PET/CT-Based Radiomics for the characterization and genetic orientation of pheochromocytomas before surgery.Cancers (Basel). 2020; 12: 2424
- Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.J Nucl Med. 2014; 55: 1253-1259
- Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.J Natl Cancer Inst. 2012; 104: 700-708
- Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.J Clin Oncol. 2007; 25: 2262-2269
- Genetic status determines (18) F-FDG uptake in pheochromocytoma/paraganglioma.J Med Imaging Radiat Oncol. 2017; 61: 745-752
- 68)Ga-somatostatin receptor analogs and (18)F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis.Acta Radiol. 2018; 59: 1466-1474
- Integrated PET/MRI with 68Ga-DOTATATE and 18F-FDG in pheochromocytomas and paragangliomas: an initial study.Clin Nucl Med. 2022; 47: 299-304
- Sporadic primary pheochromocytoma: a prospective intraindividual comparison of six imaging tests (CT, MRI, and PET/CT Using (68)Ga-DOTATATE, FDG, (18)F-FDOPA, and (18)F-FDA).AJR Am J Roentgenol. 2022; 218: 342-350
- Pheochromocytoma and paraganglioma patients with poor survival often show brown adipose tissue activation.J Clin Endocrinol Metab. 2020; 105: 1176-1185
- Detection of brown adipose tissue by (18) F-FDG PET/CT in pheochromocytoma/paraganglioma: a systematic review.J Clin Hypertens (Greenwich). 2018; 20: 615
- Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma.Eur J Nucl Med Mol Imaging. 2011; 38: 1869-1875
- 68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.Cancer Imaging. 2016; 16: 22
- Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.Eur J Nucl Med Mol Imaging. 2016; 43: 1248-1257
- The utility of (68)Ga-DOTATATE PET/CT in localizing primary/metastatic pheochromocytoma and paraganglioma in children and adolescents - a single-center experience.J Pediatr Endocrinol Metab. 2021; 34: 109-119
- The impact of Ga-68 DOTATATE PET/CT imaging on management of patients with paragangliomas.Nucl Med Commun. 2020; 41: 169-174
- Performance of (68)Ga-DOTA-Conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and Metaanalysis.J Nucl Med. 2019; 60: 369-376
- Overexpression of L-type Amino acid transporter 1 (LAT1) and 2 (LAT2): novel markers of neuroendocrine tumors.PLoS One. 2016; 11: e0156044
- Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA.Eur J Nucl Med Mol Imaging. 2017; 44: 1588-1601
- 18)F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L.Eur J Nucl Med Mol Imaging. 2017; 44: 812-821
- Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis.Eur J Nucl Med Mol Imaging. 2012; 39: 1144-1153
- 18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes.Clin Nucl Med. 2014; 39 (e53–58)
- Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.J Clin Endocrinol Metab. 2011; 96: 2779-2785
- Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.J Clin Endocrinol Metab. 2009; 94: 4757-4767
- 68)Ga-DOTATOC PET/CT in the localization of head and neck paraganglioma compared with (18)F-DOPA PET/CT and (123)I-MIBG SPECT/CT.Nucl Med Biol. 2019; 71: 47-53
- Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: a (18) F-FDOPA PET/CT study.Head Neck. 2019; 41: 1565-1571
- 18F-FDOPA PET/CT imaging of MAX-related pheochromocytoma.J Clin Endocrinol Metab. 2018; 103: 1574-1582
- Quantitative (18)F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype.Eur J Nucl Med Mol Imaging. 2018; 45: 278-282
- 15 YEARS OF paraganglioma: imaging and imaging-based treatment of pheochromocytoma and paraganglioma.Endocr Relat Cancer. 2015; 22: T135-T145
- The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.Eur J Endocrinol. 2007; 156: 483-487
- Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma.Clin Cancer Res. 2015; 21: 3888-3895
- Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.Endocr Relat Cancer. 2008; 15: 311-323
- PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma.Eur J Nucl Med Mol Imaging. 2016; 43: 1784-1791
- 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI.J Nucl Med. 2016; 57: 186-191
- Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.Clin Transl Oncol. 2021; 23: 1995-2019
- Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.J Clin Endocrinol Metab. 2014; 99: 1915-1942
- Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.Clin Endocrinol (Oxf). 2014; 81: 642-651
- SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.Int J Cancer. 2014; 135: 2711-2720
- Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma/paraganglioma-case report and review of the literature.Front Endocrinol (Lausanne). 2020; 11: 61
- SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.Endocr Relat Cancer. 2022; 29: 533-544
- A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.Br J Cancer. 2019; 120: 1113-1119
- Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.Endocrine. 2017; 57: 220-225
- Antiangiogenic therapies for pheochromocytoma and paraganglioma.Endocr Relat Cancer. 2020; 27: R239-R254
- Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas.Cancers (Basel). 2020; 12: 2307
- Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma.J Nucl Med. 2019; 60: 623-630
- EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy.Eur J Nucl Med Mol Imaging. 2008; 35: 1039-1047
- Systemic Radiopharmaceutical therapy of pheochromocytoma and paraganglioma.J Nucl Med. 2021; 62: 1192-1199
- [(177)Lu]Lu-DOTA-TATE and [(131)I]MIBG phenotypic imaging-based therapy in metastatic/inoperable pheochromocytomas and paragangliomas: comparative results in a single center.Front Endocrinol (Lausanne). 2022; 13: 778322
- Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis.Clin Endocrinol (Oxf). 2019; 91: 718-727
- Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study.Eur J Nucl Med Mol Imaging. 2022; 49: 1595-1606
- Diagnostic performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG scintigraphy in Mapping metastatic pheochromocytoma and paraganglioma.Nucl Med Mol Imaging. 2015; 49: 143-151
- A comparison of the performance of (6)(8)Ga-DOTATATE PET/CT and (1)(2)(3)I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.Eur J Nucl Med Mol Imaging. 2012; 39: 1266-1270
Article info
Publication history
Published online: December 28, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
